We are thrilled to announce the newest addition to our team – please join us in welcoming Campbell Murray MD as our new Senior Partner! With an extensive background in biotech investing and operations, Campbell brings a wealth of knowledge and expertise to our firm. His impressive track record in driving successful ventures and his passion for innovation will undoubtedly help propel our firm to new heights. We are excited to see the positive impact he will make and the new opportunities his leadership will bring as we continue to fund breakthrough science and transformative platforms that hold promise to address significant unmet medical needs. Learn more about this exciting addition to our team here: rb.gy/nsv1l2 #biotech #investment #venturecapital
About us
Bioluminescence is a leading US biotechnology venture capital firm investing in the future of medicine. We are inspired by the accelerating pace of biomedical innovation and its recent impact on humanity. We are mission-driven – investing our time, energy, and capital into translating transformative science into next-generation medicines that will impact patients. We believe that, as long as we continue to succeed in this endeavor, then strong financial returns will follow. The firm focuses investments on four areas: Breakthrough Biology, Drug Discovery Platforms, Genetic Medicines Platforms, and Computational Biology Platforms.
- Website
-
www.bioluminescence.com
External link for Bioluminescence Ventures
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
Locations
-
Primary
Get directions
501 2nd Street
San Francisco, California 94107, US
-
Get directions
245 Main St
Cambridge, Massachusetts 02142, US
Employees at Bioluminescence Ventures
Updates
-
We are excited to welcome Geney Park to the Bioluminescence team! Her background in bioengineering and clinical-stage cell therapy, and wide range of skills, including project management, organization, executive and operations support, as well as problem-solving, will be invaluable as we continue to support and invest in transformative platform technology companies that aim to make a positive impact on humanity.
-
-
What an insightful discussion! Thanks to everyone who attended yesterday’s #BIO2024 panel, as well as moderator Gwendolyn Wu and fellow panelists Carolyn Ng, Ayman AlAbdallah, and Nate Chang.
-
-
How can a strategic investment syndicate help steer a startup towards pharma partnerships and product commercialization through troubled times? Hear from BLV Partner Andy Seid and other industry-leading venture investors about the best strategies for healthcare and biotech companies to navigate volatile markets on this #BIO2024 panel. Learn about creative fundraising, lean operational models, strategic partnerships, and how these decisions can underpin sustained growth and value creation. 💸 Surviving Turbulence: Extending Runway and Creating Value in Healthcare and Biotech 🗓️ Thursday June 6 ⌚ 9 - 10 am PT 📍 32AB 🔹Gwendolyn Wu, Reporter, BioPharma Dive 🔹Nate Chang, Operating Partner, Life Sciences, Playground Global 🔹Rakhshita Dhar, Senior Director of Venture Investments Health, Leaps by Bayer 🔹Andy Seid, Partner, Bioluminescence Ventures 🔹Ayman AlAbdallah, MBA, Partner, Mubadala Capital https://lnkd.in/e3nH3fU9 #drugdiscovery #drugdelivery #innovation #drugdevelopment #business #biotech #venturecapital
-
-
Reducing time-to-market for #biopharma companies remains a critical driver of program value. How can companies accelerate product development & commercialization without compromising quality? Incorporate a patient-first approach into scientific, target-first conversations, advises BLV partner Andy Seid. See what other insights he has shared with Pharma's Almanac: https://lnkd.in/d-_S-6Qs #venturecapital #pharma #drugdevelopment #drugdelivery #biotech
-